Literature DB >> 3144657

Further behavioural evidence for the selective sedative action of zolpidem.

D J Sanger1, B Zivkovic.   

Abstract

Small doses of benzodiazepines stimulate behavioural output in experimental animals in a variety of situations. Zolpidem, which displaces benzodiazepines from their binding sites, however, has been shown to exert preferential sedative activity. In order to investigate whether small doses of zolpidem would also have stimulant effects, the actions of zolpidem and chlordiazepoxide were compared in three procedures which are sensitive to the behavioural-facilitating effects of benzodiazepines in rats. A small dose of chlordiazepoxide (3.0 mg/kg) increased locomotion in an open field whereas a large dose (30 mg/kg) suppressed this behaviour. Zolpidem (0.3-3.0 mg/kg) only decreased locomotion. The effects of both chlordiazepoxide and zolpidem were antagonised by flumazenil. Chlordiazepoxide (2.5-10 mg/kg) increased the intake of food in rats habituated to a daily feeding schedule but similar doses of zolpidem neither increased nor decreased the intake of food. Rates of punished operant responding were increased by chlordiazepoxide (3.0-30 mg/kg) but zolpidem (1.0-4.0 mg/kg) produced no such anti-punishment effect and suppressed responding at the large dose. These results show that zolpidem does not increase behavioural output in situations which are sensitive to the stimulant effects of benzodiazepines and further emphasize the selective sedative activity of this drug.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3144657     DOI: 10.1016/0028-3908(88)90007-x

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  10 in total

Review 1.  The behavioral pharmacology of zolpidem: evidence for the functional significance of α1-containing GABA(A) receptors.

Authors:  Amanda C Fitzgerald; Brittany T Wright; Scott A Heldt
Journal:  Psychopharmacology (Berl)       Date:  2014-02-22       Impact factor: 4.530

Review 2.  Zolpidem. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential.

Authors:  H D Langtry; P Benfield
Journal:  Drugs       Date:  1990-08       Impact factor: 9.546

3.  State-dependent effects of atypical benzodiazepine-receptor agonists.

Authors:  A Jackson
Journal:  Psychopharmacology (Berl)       Date:  1995-06       Impact factor: 4.530

4.  Enhanced sucrose pellet consumption induced by benzodiazepine-type drugs in squirrel monkeys: role of GABAA receptor subtypes.

Authors:  Angela N Duke; Donna M Platt; James M Cook; Shengming Huang; Wenyuan Yin; Bruce A Mattingly; James K Rowlett
Journal:  Psychopharmacology (Berl)       Date:  2006-06-17       Impact factor: 4.530

5.  Emergence of anti-conflict effects of zolpidem in rhesus monkeys following extended post-injection intervals.

Authors:  James K Rowlett; John H Kehne; Ken J Sprenger; George D Maynard
Journal:  Psychopharmacology (Berl)       Date:  2010-11-20       Impact factor: 4.530

6.  Effect of the benzodiazepine receptor agonist, zolpidem, on palatable fluid consumption in the rat.

Authors:  K J Stanhope; S Roe; G Dawson; F Draper; A Jackson
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

7.  Benzodiazepines and heightened aggressive behavior in rats: reduction by GABA(A)/alpha(1) receptor antagonists.

Authors:  Shannon L Gourley; Joseph F Debold; Wenyuan Yin; James Cook; Klaus A Miczek
Journal:  Psychopharmacology (Berl)       Date:  2004-08-17       Impact factor: 4.530

Review 8.  Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: zaleplon, zolpidem and zopiclone.

Authors:  David R Drover
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

9.  EEG profile of intravenous zolpidem in healthy volunteers.

Authors:  A Patat; S Trocherie; J J Thebault; P Rosenzweig; C Dubruc; G Bianchetti; L A Court; P L Morselli
Journal:  Psychopharmacology (Berl)       Date:  1994-02       Impact factor: 4.530

10.  Novelty and anxiolytic drugs dissociate two components of hippocampal theta in behaving rats.

Authors:  Christine E Wells; Doran P Amos; Ali Jeewajee; Vincent Douchamps; John Rodgers; John O'Keefe; Neil Burgess; Colin Lever
Journal:  J Neurosci       Date:  2013-05-15       Impact factor: 6.167

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.